Literature DB >> 19382999

Rituximab-induced vasculitis: A case report and review of the medical published work.

Min Joo Kim1, Hyung Ok Kim, Ho Yeon Kim, Young Min Park.   

Abstract

Rituximab is an anti-CD20 chimeric murine/human monoclonal antibody mainly used in the treatment of patients with a cutaneous lymphoid malignancy. Among the side-effects associated with rituximab administration, vasculitis has been rarely reported. There are two reported cases in the English language medical published work. We describe a 38-year-old Korean man with cutaneous vasculitis occurring 1 day after rituximab administration.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19382999     DOI： 10.1111/j.1346-8138.2009.00639.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


  12 in total

1.  Multiple eruptive periungual pyogenic granulomas during anti-CD20 monoclonal antibody therapy for rheumatoid arthritis.

Authors:  Uwe Wollina
Journal:  J Dermatol Case Rep       Date:  2010-12-19

2.  An Elderly Man with Fatigue, Dyspnea, and Kidney Failure.

Authors:  Andrew S Bomback
Journal:  Clin J Am Soc Nephrol       Date:  2017-03-08       Impact factor: 8.237

Review 3.  Targeting B cells and antibody in transplantation.

Authors:  M R Clatworthy
Journal:  Am J Transplant       Date:  2011-06-10       Impact factor: 8.086

Review 4.  Adverse reactions to biologic agents and their medical management.

Authors:  Onur Boyman; Denis Comte; François Spertini
Journal:  Nat Rev Rheumatol       Date:  2014-08-12       Impact factor: 20.543

Review 5.  Rheumatoid vasculitis: vanishing menace or target for new treatments?

Authors:  Christie M Bartels; Alan J Bridges
Journal:  Curr Rheumatol Rep       Date:  2010-12       Impact factor: 4.592

6.  Ixazomib-induced cutaneous necrotizing vasculitis.

Authors:  A Alloo; H Khosravi; S R Granter; S M Jadeja; P G Richardson; J J Castillo; N R LeBoeuf
Journal:  Support Care Cancer       Date:  2018-02-01       Impact factor: 3.603

7.  Rituximab in severe skin diseases: target, disease, and dose.

Authors:  Daniel D Bennett; Maro Ohanian; Christian T Cable
Journal:  Clin Pharmacol       Date:  2010-07-07

Review 8.  Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.

Authors:  Brian A Baldo
Journal:  Oncoimmunology       Date:  2013-10-17       Impact factor: 8.110

Review 9.  Drug-Induced Vasculitis: New Insights and a Changing Lineup of Suspects.

Authors:  Rafael G Grau
Journal:  Curr Rheumatol Rep       Date:  2015-12       Impact factor: 4.686

10.  Epidermolysis bullosa acquisita as an adverse effect from rituximab therapy: A case report.

Authors:  Xueqiong Wu; Zhenhui Lv; Wenjia Li; Zhaosheng Meng; Shaw P Wan
Journal:  Medicine (Baltimore)       Date:  2020-12-04       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.